{"id":"W2980054153","doi":"10.1182/blood.v120.21.1633.1633","title":"An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Calicheamicin; Internal medicine; Adverse effect; Rituximab; Gastroenterology; Refractory (planetary science); Lymphoma; Neutropenia; Regimen; Vincristine; Febrile neutropenia; Cyclophosphamide; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001655875,0.001597019,0.002513189,0.0004768062,0.0005481437,0.001185883,0.001123184,0.001235978,0.002959605],"category_scores_gemma":[0.001158401,0.0007914052,0.001098373,0.0004373832,0.001217642,0.001439286,0.000372715,0.004013193,0.0008882335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106597,"about_ca_system_score_gemma":0.00166333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006522185,"about_ca_topic_score_gemma":0.002079683,"domain_scores_codex":[0.9994208,0.0002767872,0.00002575689,0.0001161621,0.00005662089,0.0001039983],"domain_scores_gemma":[0.9991198,0.000179008,0.0001623094,0.00008948111,0.0000572844,0.0003920492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6725061,0.1713399,0.004876017,0.0008924832,0.001381954,0.0003908428,0.0005739604,0.002496468,0.05538883,0.0003178116,0.003893853,0.08594186],"study_design_scores_gemma":[0.4567551,0.5278236,0.008258301,0.00002950257,0.0003281492,0.0002472579,0.00006925298,0.001101458,0.003177362,0.0001972003,0.001981191,0.00003162732],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938877,0.001352392,0.0006172913,0.0002382056,0.0000958986,0.001981308,0.0006247938,0.00008124005,0.001121347],"genre_scores_gemma":[0.9916181,0.001082031,0.001565836,0.0005103589,0.0001900216,0.002499697,0.001137919,0.00003526099,0.001361011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002959605,"threshold_uncertainty_score":0.009900868,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01977297355927289,"score_gpt":0.298823900790615,"score_spread":0.2790509272313421,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}